Greehey CCRI ZOOMinar Series Presents: Arvin Dar, PhD, Mount Sinai

Event Date & Time

December 3, 2021 at 11:00 am - 12 noon


Event Details:
Presentation Title: Chemical Genetic Discovery of Cancer Targets and Anti-Targets’

Greehey CCRI Faculty Host: Yogesh Gupta, PhD.

Meeting ID: 914 0902 1393

Passcode: Zoominar_1


11:00pm – 12:00pm CST      SEMINAR


Save to Calendar

Add to Calendar

About the Speaker(s)

Arvin Dar, PhDArvin Dar is Associate Professor, Oncological Sciences and Pharmacological Sciences, and Associate Director of the Mount Sinai Center for Therapeutic Discovery. With a training focus on structural biology and small molecule design and synthesis, Dr. Dar conducts research on developing new therapeutic approaches for disease, particularly small molecule modulators for targeting RAS-driven cancers. His work provides insights into the regulation of oncogenic RAS and offers a foundation for the development of targeted compounds that alter oncogenic signaling complexes. Dr. Dar’s laboratory also investigates target discovery for other disease areas, including hepatocellular carcinoma and rare genetic disorders such as RASopathies and tauopathies. Dr. Dar has received the NIH Director’s New Innovator Award, Damon-Runyon Rachleff Innovation Award, Pew-Stewart Scholarship for Cancer Research, and grant support from the Pershing Square Sohn Cancer Research Alliance, as well as other extramural funding.

Arvin Dar, PhD Mt Sinai Profile

Dar Lab




Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to the understanding of its causes, and accelerate the translation of knowledge into novel therapies. Through discovery, development, and dissemination of new scientific knowledge, Greehey CCRI strives to have a national and global impact on childhood cancer. Our mission consists of three key areas — research, clinical, and education.

Stay connected with the Greehey CCRI on FacebookTwitterLinkedIn, and Instagram.